James Healy - Jan 30, 2024 Form 4 Insider Report for ArriVent Biopharma, Inc. (AVBP)

Role
Director
Signature
/s/ James Kastenmayer, Attorney-in-Fact for James Healy
Stock symbol
AVBP
Transactions as of
Jan 30, 2024
Transactions value $
$7,999,992
Form type
4
Date filed
1/31/2024, 04:10 PM
Previous filing
Jan 30, 2024
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVBP Common Stock Conversion of derivative security +1.25M 1.25M Jan 30, 2024 Sofinnova Venture Partners XI, L.P. F1, F2
transaction AVBP Common Stock Purchase $8M +444K +35.49% $18.00* 1.7M Jan 30, 2024 Sofinnova Venture Partners XI, L.P. F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVBP Series B Preferred Stock Conversion of derivative security -1.25M -100% 0 Jan 30, 2024 Common Stock 1.25M Sofinnova Venture Partners XI, L.P. F1, F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-15.21 basis.
F2 The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
F3 Reflects shares purchased in the Issuer's initial public offering.
F4 The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.
F5 Not applicable.